First Subject Dosed in Phase I Multiple Ascending Dose (MAD) Study of LAE102 for the Treatment of Obesity
December 22, 2025
Source: drugdu
28
SouthCN, Dec 22 (Report) — Laekna (2105.HK) announced on the HKEX on the morning of December 22 that the Group has launched subject enrollment for its Phase I Multiple Ascending Dose (MAD) study of LAE102 for the treatment of obesity in China, with the first subject already successfully dosed.
https://finance.eastmoney.com/a/202512223597697444.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Nxera seeks schizophrenia programme buyer after Boehringer snub December 22, 2025
- First innovative traditional Chinese medicine for frequent tension headaches launched. December 22, 2025
- The battle for rivaroxaban intensifies! Guilin Pharmaceutical enters the fray with its first generic dry suspension December 22, 2025
- Another biotech company goes bankrupt December 22, 2025
- Phase III Clinical Trial of Innovative Prostate Cancer Diagnostic Radiopharmaceutical TLX591-CDx Reaches Primary Endpoint in China December 22, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
